More recent evidence suggests that patients with anti-gp210 antibodies were more likely to develop interface hepatitis and lobular inflammation, akin to that in scurfy mice and PBC-AIH overlap syndrome (20, 31, 40). The gene discussed is NUP210; the disease is primary biliary cholangitis.